NAPLES, Fla., November 9, 2020 (Newswire.com) – Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed pharmaceutical industry veteran Daniel Motto as its Chief Business Officer.
Dan brings more than 20 years of experience in the pharmaceutical industry managing a broad range of functions including commercial, business development, portfolio management, business intelligence and finance. He has led the evaluation of hundreds of product opportunities and has executed transactions with partners around the world. Dan was most recently Executive Vice President and head of the commercial organization and supporting functions for the U.S. hospital business of Hikma Pharmaceuticals, one of the largest suppliers of injectable medicines to the U.S. market.
“I am thrilled to be a member of the Enalare leadership team, helping to build the company and advance our novel lead drug candidate ENA-001 for acute respiratory depression. This is an area where there has been a lack of innovation for more than five decades, yet each year, millions of patients are severely impacted by respiratory depression across multiple settings. There is a dire need for new treatment options,” stated Dan Motto, “and I am very pleased to have this opportunity to make a difference in patient care.”
“I am excited to partner with Dan as we advance Enalare’s pipeline of compounds, both through our own activities and external partnering. We see a tremendous opportunity to bring our products to patients around the globe and Dan’s unique background and market knowledge will help us to achieve this goal,” stated Enalare’s President and CEO, Herm Cukier.
Prior to his role at Hikma, Dan led key global functions including business development and product portfolio strategy for large multinational companies such as Actavis, Allergan and Teva. He was a member of the Global Leadership and Operational Leadership teams, driving growth through organic initiatives and significant M&A transactions. Dan has also held management positions at Novartis and started his pharmaceutical career at Johnson & Johnson, working on the launch of the first long-acting injectable medicine in the CNS therapeutic category. Dan received his MBA and an MS in Engineering from Cornell University, and BS from Rutgers University.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, including respiratory depression caused by drug overdose, post-surgery, and COVID-19. The Company is planning to initiate pivotal studies in the U.S. for its lead compound ENA-001.
Enalare Investor Relations
Source: Enalare Therapeutics Inc.